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Abstract
Background: About 90 % of all persons with mild Alzheimer’s disease experience neuropsychiatric symptoms, most
frequently apathy, depression, anxiety and irritability. These symptoms are associated with greater morbidity, a
reduced quality of life for the patient, an increased burden and depression for the caregiver, and higher costs of
care and nursing home placement. Psychosocial interventions based on behaviour therapy represent the most
efficacious treatment of neuropsychiatric symptoms. However, there is no study, to our knowledge, that has
evaluated a multicomponent treatment programme based on comprehensive, cognitive behavioural therapy (CBT).
This randomized controlled trial aims to evaluate a CBT-based treatment programme consisting of 8 modules and
25 sessions.
Methods/design: Fifty patients with mild Alzheimer’s disease alone or with mild mixed dementia (Alzheimer’s
disease and vascular dementia) who have any neuropsychiatric symptom will be included. A caregiver must be
available. The patients and their caregivers will be randomized to either the CBT-based intervention group or to the
control condition group, which receives treatment as usual. The primary outcome measure is depression in the
patient with Alzheimer’s disease. The secondary outcome measures for a person with Alzheimer’s disease are other
neuropsychiatric symptoms, quality of life and coping strategies. The secondary outcome measures for a caregiver
are caregiver’s burden, depression, anxiety, anger, quality of life and coping strategies. Neuropsychological testing
includes tests of cognitive function and activities of daily living and a global clinical assessment of severity.
Participants in both groups will be assessed before and after the treatment phase (lasting approximately 9 months).
Follow-up assessments will take place 6 and 12 months after treatment. All assessments will be conducted by
blinded assessors.
Discussion: This trial has the potential to establish an empirically based psychological treatment for non-cognitive
symptoms that reduce the quality of life of a person with dementia and a caregiver. This treatment approach
focuses not only on the person with dementia, but also on the caregiver and on the dyad. The treatment manual
will be published and training workshops will be offered, so that the information can be widely spread among
healthcare professionals.
Trial registration: ClinicalTrials.gov NCT01273272.
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Background
Alzheimer’s disease is a chronic debilitating mental con-
dition manifested by cognitive and memory deterior-
ation, progressive impairment in performing the
activities of daily living and a variety of neuropsychiatric
symptoms and behavioural disturbances. In 2006, the
worldwide prevalence of Alzheimer’s disease was 26.6
million; this number is predicted to quadruple by 2050
[1]. Mild cases of Alzheimer’s disease make up the lar-
gest proportion of all Alzheimer’s disease cases, with 15
million worldwide.
The medical problem
Neuropsychiatric symptoms are very common among
patients with Alzheimer’s disease [2]. Affective and be-
havioural symptoms may be present in early dementia or
emerge later in the course of the illness. The most fre-
quent disturbances in mild Alzheimer’s disease are ap-
athy, depression, anxiety and irritability, with a total
prevalence estimated to be up to 92 % [3]. Almost all pa-
tients with Alzheimer’s disease are affected by neuro-
psychiatric symptoms at some point. Even with mild
cognitive impairment, a condition characterized by cog-
nitive deficits without an impairment in functional activ-
ities, 35–73 % of patients experience neuropsychiatric
symptoms [4]. Neuropsychiatric symptoms are associ-
ated with greater morbidity and a reduced quality of life
for the patient, as well as an increased burden and de-
pression for the caregiver [5] and higher costs of care
[6]. They are also associated with the increased use of
psychotropic medications and increased patient and
caregiver abuse [7]. Neuropsychiatric symptoms are a
primary predictor of nursing home placement [8]. Thus,
interventions aimed at treating these symptoms might
have a tremendous effect on patients, caregivers and
society.
Evidence for psychosocial interventions
A whole variety of different approaches can be
described as psychosocial (or non-pharmacological)
interventions for dementia patients [9]. However, em-
pirical evidence is lacking for many of the ap-
proaches, as some reviews have concluded [9–11].
The proposed study is aimed at meaningfully combin-
ing interventions whose effectiveness is empirically
supported. In their wide-ranging and comprehensive
review, Livingston et al. [10] rated a number of ap-
proaches by the level of evidence and graded their
recommendation of each approach, based on the Ox-
ford Centre for Evidence-Based Medicine criteria. The
only approaches that received the highest grade of
recommendation were behavioural management tech-
niques focused on the caregiver, including psychoedu-
cation and interaction training. At second position
were behavioural management techniques focused on
the person with dementia, including techniques focus-
ing on pleasant activities and problem solving, multi-
sensory stimulation, active music therapy and
cognitive stimulation. The guidelines published by the
UK National Collaborating Centre for Mental Health
[11] concluded that, based on the evidence, behav-
ioural management was most effective in reducing a
challenging behaviour, while cognitive behavioural
therapy (CBT) was most effective in reducing depres-
sion and anxiety in people with dementia. Thus, a
psychosocial intervention based on (cognitive) behav-
iour therapy seems to be one of the most promising
treatments of non-cognitive symptoms in patients
with Alzheimer’s disease. Next, we summarize evi-
dence for concrete cognitive behavioural and related
interventions, which are easily integrated into a CBT
approach.
Engagement in pleasant or structured activities
Teri et al. [12] reported empirical evidence from a
controlled clinical trial of two CBT-based interven-
tions to treat depression in people with Alzheimer’s
disease. One treatment involved increasing engage-
ment in pleasant activities and events and the other
involved behavioural problem-solving strategies. The
participants in both intervention groups showed sig-
nificant improvements in depressive symptoms com-
pared with those in the two control groups, and
these improvements were maintained for 6 months
after the trial. The ‘pleasant events’ treatment re-
sulted in a large effect size (d = 0.9–1.7 for three dif-
ferent depression measures), with 52 % clinically
significant improvement (versus 20 % in the control
groups). In addition, there were also significant
improvements in caregivers’ depression scores, but
no improvement for the caregivers in the control
groups. Increasing engagement in pleasant activities,
including social, physical and leisure activities, is not
only important for reducing depression, but also de-
creases the amount of daytime sleep taken, improves
night-time sleep [13] and reduce wandering, aggres-
sion and agitation [14].
Training caregivers in behaviour management techniques
In a randomized controlled trial, exercise and behaviour
management techniques led to significant improvements
in depression and physical health, e.g., behavioural inter-
vention reduced symptoms of depression more than
twice as much as routine medical care [15]. Behaviour
management techniques are also effective in improving
food intake [16], reducing urinary incontinence [17] and
improving functional abilities, such as dressing [18].
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Interventions for the caregiver
Caring for a patient with Alzheimer’s disease is asso-
ciated with a severe negative impact on the caregiver’s
health. In caregivers of patients with Alzheimer’s dis-
ease, the prevalence of depressive disorders is 22 %
[19] and that of anxiety is 25 % [20]. Therefore, much
research has focused on psychosocial interventions for
caregivers of patients with dementia [21, 22]. Inter-
ventions to improve the health status of caregivers
also have positive effects on neuropsychiatric symp-
toms of patients with Alzheimer’s disease. Therefore,
a comprehensive treatment approach with a focus on
patients’ mental health should also include interven-
tions to reduce the burden on their caregivers. The
treatment effect was found to be higher when the
intervention included CBT-based psychotherapy [23],
the number of sessions was more than ten, both care-
giver and patient were involved and the treatment
was individualized [21]. Effect sizes of CBT interven-
tions were on average medium (d = 0.68) [21] or large
(d = 1.20) [23] with regard to mood measures (depres-
sion, anxiety).
Cognitive restructuring
As well as behavioural techniques, cognitive restruc-
turing is one of the major techniques in CBT. In
their cognitive model of depression, Beck et al. [24]
describe cognitive schemas as core components of
emotional disorders, e.g., a negative view of oneself,
the world and the future (the ‘cognitive triad’) in the
case of depression. Cognitive behavioural therapy in-
cludes strategies to change those negative thoughts
and beliefs. Since the individual’s ability for introspec-
tion and reflection is a prerequisite of cognitive re-
structuring, and this ability is progressively impaired
in dementia, it has been suggested that this technique
is most likely to benefit patients with mild dementia
[25]. The point beyond which cognitive restructuring
is not useful anymore has yet to be identified. There
has been no randomized controlled trial yet, but case
studies recommend the potential use of cognitive
techniques for patients with mild Alzheimer’s disease
[26, 27]. Clearly, some modifications are necessary,
e.g. simplifying the material, enhancing encoding by
having the patient repeat information, using reminder
cards with helpful thoughts and involving caregivers
to facilitate learning at home.
Structured life review
A structured life review was shown to be effective in
treating depression in older people [28, 29]; in fact, it is
among the most effective treatments for depression in
older age [30]. A structured life review involves individ-
ual sessions, in which a person is guided chronologically
through life experiences and is encouraged to evaluate
them [31, 32]. It is more effective than unstructured
reminiscence therapy, one of the most popular psycho-
social interventions in dementia (effect size: 0.92 versus
0.46, respectively) [28]. A life review is increasingly used
for people with dementia [33] and is effective in redu-
cing their depression [34, 35]. Effect size is in average
small for cognition (g = 0.33) and depression (g = 0.31)
[29]. It helps patients with Alzheimer’s disease gain ac-
cess to past memories and thereby enhances their sense
of personal identity, maintains their self-worth and offers
them a pleasurable experience.
Couples counselling
All previous psychotherapeutic strategies have focused
either on the patient with Alzheimer’s disease or the
caregiver. Recent research tries to treat a couple facing
Alzheimer’s disease as a unit that needs to be the focus
of the treatment. To be a partner of the other is one of
the greatest resources for both the patient and the
spouse, and psychotherapy should aim at improving the
marital relationship, communication and the attitude to
face the future more optimistically and collaboratively.
The typical topics covered in couples counselling are:
expressing and discussing fears openly; gradually chal-
lenging the view that everything is continuing normally;
adapting to new roles (dependence, responsibility); im-
proving communication style; establishing joint activ-
ities; identifying old and new coping strategies; and
maintaining important elements of the former relation-
ship despite the changes necessitated by the illness [36].
A further frequent topic is the joint planning of future
care, with a discussion of uncertainties and worries ex-
perienced by the patient and the caregiver [37]. The first
results of an intervention study of couples counselling
are very encouraging [38]; however, there were no re-
sults from randomized controlled trials at the time of
writing.
While there is good evidence for most of the afore-
mentioned psychotherapeutic approaches, there have
been only a few attempts to evaluate a comprehensive
CBT programme including (almost) all of the described
strategies. We outlined our comprehensive CBT
programme, as described next, in a German textbook
[39]. Several case studies have been described, which in-
clude engagement in pleasant activities, behaviour man-
agement techniques and cognitive restructuring, but not
life review, couples counselling, and interventions for
the caregiver [40, 41]. A randomized controlled trial
with a brief CBT-based intervention, including struc-
tured activities and a life review, has recently been
conducted, with mixed results (a significant reduction
only in female participants) [42]. Furthermore, self-
maintenance therapy, a short-term residential treatment
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programme with CBT elements, a life review and inter-
ventions for the caregiver resulted in a significant de-
crease in depression and problematic behaviour
compared with the baseline [43].
Not only are efficacy data missing for a comprehensive,
multicomponent, CBT-based treatment programme, but
most previous studies exhibited methodological weak-
nesses, such as the lack of an adequate control condition,
outcome measures restricted in number and domain and
involvement of either the patient or the caregiver but not
both.
Rationale for the current study
The current study combines theory-based, multicompo-
nent intervention strategies, whose efficacy has been
demonstrated in randomized controlled trials or sup-
ported by case studies, with state-of-the-art trial meth-
odology. The study tries to overcome the shortcomings
of previous research in several respects: (1) the interven-
tions are based on established psychological models; (2)
CBT strategies will be consistently applied; (3) a high
quality of treatment and consistency in treatment deliv-
ery will be ensured by using trained psychotherapists
with specialized training in the intervention programme
and regular supervision during the study; (4) the targets
of the interventions will be the patient with Alzheimer’s
disease, the caregiver and the dyad; (5) the treatment
will be structured, but also individualized according to
individual problems; (6) a randomized, controlled,
assessor-blinded study design will be employed; (7) vari-
ous outcome measures, involving various domains of the
patient’s and caregiver’s health, will be applied; (8) statis-
tical power calculations will be used to estimate the
sample size.
A modular and non-uniform programme is justified
because no single strategy would achieve the treatment
goal to the desired extent. Modular programmes are also
common for other mental disorders, e.g. dialectical be-
havioural therapy for treating borderline personality dis-
order or CBT for treating depression.
The trial manual includes eight modules. The content
of the sessions is described in an unpublished manual.
Because the patient and the caregiver will have different
symptomatologies (e.g., depression, apathy, anxiety and
irritability) and varying degrees of marital problem, cer-
tain modules may be more important than others.
Therefore, the therapist can assign different weights to
the eight modules, while still conforming to the study
protocol. The modules are as follows:
1. Diagnosis and goal setting This first module includes
a thorough diagnosis of emotional and behavioural
problems of the patient and caregiver, a behaviour
analysis of the situation, including behaviours,
emotions, cognition and consequences and
individual goal setting. A therapeutic alliance will be
developed during this phase and motivation for
change is encouraged by the therapist [44].
2. Psychoeducation Sometimes, but not always, patients
and caregivers are inadequately informed of the
diagnosis of Alzheimer’s disease, its causes, course
and treatment options. If this is the case, the
therapist provides appropriate information.
Psychoeducation is not efficacious in reducing
symptoms as a stand-alone intervention [10], but is
a motivational prerequisite for change. Part of psy-
choeducation is information and training on adopt-
ing external memory aids. This is not an efficacious
intervention on its own either [45], but these strat-
egies are needed to support subsequent intervention
and related therapeutic tasks.
3. Engagement in pleasant activities Based on the
behavioural theory of depression [46], the patient is
helped to increase the number and frequency of
pleasant activities engaged in and to adopt a
structured weekly schedule. Social, physical and
other leisure activities are included.
4. Cognitive restructuring Based on the cognitive model
of emotional disorders [24], dysfunctional thoughts
(depression, anxiety or anger related) will be
recorded and discussed and alternative, helpful
thoughts will be practised.
5. Life review The structured life review that we adopt
in our intervention programme [31, 32] is based on
Erik Erikson’s eight stages of man [47]. In each life
review session, one or two of Erikson’s stages are
applied to the life of the patient. The patient is
guided chronologically through life experiences and
is encouraged to evaluate them. Photographs, music
and other artefacts are used to support
reminiscence.
6. Training caregiver in behaviour management
techniques The system model of behaviour
regulation [44] describes each problem behaviour as
triggered by precursors and followed by
consequences (similar to the ‘ABC of behaviour
change’ outlined by Teri et al. [48, 15]). Strategies to
change precursors and consequences are planned,
and the caregiver is trained in applying them.
7. Interventions for the caregiver Interventions with the
aim of improving the caregiver’s well-being, stress
management and emotional regulation (e.g. anger
management) and social support are mainly deliv-
ered to the caregiver in sessions without the patient
and in parallel with patient sessions. These treat-
ment strategies are based on the cognitive model of
emotional disorders [24], the system model of be-
haviour regulation [44] and the buffering theory of
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social support [49]. Interventions from modules 3
and 4 are used; however, the focus of this module is
on the caregiver and not on the patient or the dyad
(module 8).
8. Couples counselling The vulnerability–stress–
adaptation model of marriage [50] assumes that
vulnerability factors (e.g. attachment style) and
stressful events (e.g. dementia) impact the adaptive
competencies of a couple. The adaptive processes
(e.g. communication, joint coping) influence, in turn,
the stressor and marital satisfaction. Therefore, a
few sessions, which are focused on expressing fears,
adapting to new roles, improving communication
and joint coping, establishing joint activities and
planning for the future, are included. To help the
couple to talk about the relationship and develop a
positive attitude towards couples counselling, an oral
history interview is used [51].
Study objectives
The goal of this study is to evaluate the effect of a CBT-
based, multicomponent treatment programme on the
health of patients with mild Alzheimer’s disease and
their caregivers. The main focus is to improve the pa-
tients’ health, but the inclusion of the caregivers is ne-
cessary because there is a reciprocal interaction between
the well-being of patients and their caregivers. We ex-
pect, in comparison with the control condition, a signifi-
cant decrease in depressive and other neuropsychiatric
symptoms and an improvement in functional abilities,
quality of life and adaptive coping strategies, including
social support, for the patient. Also expected are a de-
crease in depressive, anxiety and anger symptoms and
the burden of providing care and improvements in the
quality of life and adaptive coping strategies, including
social support, for the caregiver.
Methods/design
Design
This is a randomized, controlled, assessor-blinded,
follow-up study, which includes patients with mild Alz-
heimer’s disease and their caregivers. The patients and
their caregivers will be randomized to either the CBT-
based intervention group or to the control condition
group, which receives treatment as usual.
Intervention condition (cognitive behavioural therapy)
The CBT-based, multicomponent treatment programme
consists of 25 weekly or biweekly sessions. It includes
the following eight modules: diagnosis and goal setting;
psychoeducation; engagement in pleasant activities; cog-
nitive restructuring; life review; training the caregiver in
behaviour management techniques; interventions for the
caregiver; and couples counselling. While the treatment
is conducted according to the manual, it is to be individ-
ualized according to individual problems of the patient
and the caregiver. The interventions are described next
in more detail.
Control condition (treatment as usual)
The patients in the control condition group receive
standard medical and psychosocial care, which is treat-
ment as usual at the Psychiatric University Hospital Zur-
ich. We have operationalized the treatment-as-usual
condition in such a way that it is partly manualized, but
still individualized. Each patient or caregiver must re-
ceive at least three out of the six interventions: (1) psy-
choeducation on dementia and its treatment (oral and
written); (2) appropriate medical treatment; (3) social
counselling by specialized staff; (4) memory training in a
group setting; (5) a self-help group for the patient; and
(6) a self-help group for the caregiver. Thus, patients re-
ceive usual care with minimal support, which is ethically
acceptable, since the standard treatment is implemented
in the control condition. At the same time, using this
control condition is methodologically appropriate be-
cause the likelihood of a significant effect is expected to
be smaller than that in the intervention condition.
Moreover, the recruitment of study subjects will not be
compromised by using this treatment-as-usual control
condition. Members of the staff of the Psychiatric Uni-
versity Hospital Zurich, who are independent of the
CBT interventionists, will provide the control
intervention.
Enrolment into one of the two conditions will be done
consecutively during the recruitment phase. The treat-
ment phase takes an estimated average of 9 months (in-
cluding 25 weekly or biweekly sessions in the CBT
condition). The participants in both conditions will be
assessed before and after the treatment phase. Follow-up
assessments will take place 6 and 12 months after treat-
ment. All assessments will be conducted by blinded as-
sessors. A CONSORT-style flow chart for the trial is
shown in Fig. 1.
Participants
Recruitment
The participants will be recruited from three sources:
(1) the Psychiatric University Hospital Zurich, Depart-
ment of Gerontopsychiatry; (2) the outpatient clinic
of the University of Zurich, Department of Psycho-
pathology and Clinical Intervention; and (3) other
geriatric or memory clinics and general practitioners
in the greater area of Zurich. Patients are referred to
our two clinics either for confirmation of possible de-
mentia at the memory clinic of the Psychiatric Uni-
versity Hospital Zurich or for treatment of affective
symptoms. Since mild cases of Alzheimer’s disease are
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often treated by a general practitioner until the symp-
toms progress to a moderate stage, the network of
general practitioners in Zurich complements recruit-
ment at our two clinics and other clinics. Patients re-
cruited via a general practitioner will receive a
thorough neuropsychological and medical assessment
at the Psychiatric University Hospital Zurich.
Inclusion and exclusion criteria
Patients must meet the criteria of the National Insti-
tute of Neurological and Communicative Disorders
and Stroke – Alzheimer’s Disease and Related Disor-
ders Association (NINCDS–ADRDA) for probable or
possible Alzheimer’s disease [52]. Mixed Alzheimer’s
and vascular dementia cases will also be included.
Only cases of Alzheimer’s disease with a mild severity
of dementia will be included, as determined by the
Clinical Dementia Rating Scale (i.e., scores of 0.5 or
1) [53] and by the Mini Mental State Examination
(i.e., scores of 20 or more) [54]. The patient must ex-
perience any non-cognitive symptom that motivates
the acceptance of psychotherapeutic help. Typically,
symptoms of depression, apathy, anxiety or irritability
are present at the time of enrolment. A caregiver
must be available to take part in most of the psycho-
therapy sessions. This is typically the partner, but a
child or a good friend, who is able to take responsi-
bility for reminding the patient about therapeutic
tasks, is also accepted.
Exclusion criteria are a concomitant alcohol or drug
addiction and a history of a malignant disease, severe
organ failure, metabolic or haematological disorders,
neurosurgery or a neurological condition, such as Par-
kinson’s disease, epilepsy, postencephalitic or postcon-
cussional syndrome.
Informed consent
The objectives and goals and detailed information
about the assessment and therapy, as well as the pro-
cedure of randomization, will be explained to the sub-
jects. The information will also be given in printed
form to the subjects. Written informed consent will
be obtained from all participants and caregivers prior
to inclusion. Patients who cannot give their informed
consent will not be included in the study.
Fig. 1 Trial design and CONSORT flow diagram. CBT, cognitive behavioural therapy; TAU, treatment as usual
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Withdrawal criteria
Participation in the study is voluntary. There are no
negative consequences for non-participation or dropping
out. Patients who deny participation or drop out will re-
ceive medical and psychosocial care as usual.
Sample size
Previous studies of the interventions for patients with
mild Alzheimer’s disease included in our multicompo-
nent treatment programme found small-to-medium ef-
fect sizes for depression outcomes (d = 0.4 to 0.6,
corresponding to f = 0.2 to 0.3) [12, 15, 21, 43]. We base
our sample size calculation on the assumption of a
small-to-medium effect size for depression as measured
using the Geriatric Depression Scale (d = 0.5, f = 0.25).
The sample size was calculated using G*Power 3.1.0
software [55]. Assuming α = 0.05 and a test power 1 − β =
0.80, a total sample size of n = 44 is required to test condi-
tion × time interactions in an analysis of variance
(ANOVA) with repeated measurements (r = 0.3). Since
previous studies on CBT-based psychotherapy for care-
givers of people with dementia found medium [21] or
large [23] effect sizes on mood measures (depression, anx-
iety), this sample size should also be sufficient to find an
effect of the intervention on caregiver’s mood. We assume
a rather conservative rate of loss of 60 % from the screen-
ing of eligibility to the enrolment of subjects. Thus, we
propose to start with approximately 120 patients and care-
givers at the screening, which we expect to reduce to 50 at
enrolment. A drop-out rate of approximately 10 % would
lead to n = 44.
Randomization
After providing informed consent and receiving a base-
line assessment, the participating couples will be indi-
vidually randomized. The allocation ratio for
randomization into either the intervention or control
condition is 1:1. The randomization will be performed
by a computer algorithm independently operated by the
Clinical Trial Centre of the University Hospital Zurich.
The results of the randomization will be sent to the
study nurse, who will telephone the participant and the
caregiver to explain the next steps.
Cognitive behavioural therapy intervention
Session content and setting
The CBT-based, multicomponent treatment programme
consists of 25 sessions, mostly 60 mins in duration. The
first two sessions (diagnosis and behaviour analysis) may
take up to 90 mins. Table 1 details the content of all ses-
sions. Most of them are joint sessions, but some are sep-
arate sessions with either the patient or the caregiver.
The sessions of module 7 (interventions for the care-
giver) are not prescribed by number, but as many are
delivered as needed. They are conducted in parallel with
sessions 4 to 16, with a variable time between the ses-
sions starting after session 3. All sessions occur in rooms
of the Psychiatric University Hospital Zurich, Depart-
ment of Gerontopsychiatry, or at the outpatient clinic of
the University of Zurich, Department of Psychopath-
ology and Clinical Intervention.
Therapeutic techniques
The majority of the therapeutic techniques stem from
the CBT literature, including behaviour analysis, psy-
choeducation, advice on establishing pleasant activities,
guidance on self-reward to motivate oneself, cognitive
restructuring through Socratic dialogue and guided dis-
covery, training in behaviour management, problem
solving and stress management. The life review, though
not a CBT technique in origin, is used in a highly struc-
tured variant to fit into the general CBT approach. The
techniques in the couples counselling sessions, which do
not belong to traditional CBT either, mainly include
adopted behavioural strategies, i.e., training in communi-
cation and problem solving, planning and cognitive
restructuring.
Psychotherapists
The CBT treatment programme will be administered by
trained psychotherapists with a master’s degree in psych-
ology or medicine and a qualification in CBT. Further-
more, all participating psychotherapists will be trained
for this novel intervention by a panel of experts and su-
pervisors in the field of CBT for older age (SF and AM).
A 2-day workshop will precede the intervention phase.
Supervision sessions will take part every month (i.e.,
about five sessions per patient). All sessions will be doc-
umented in a structured form and reflected upon in the
supervision sessions.
Standardization of procedures
The therapeutic strategies and material for each session
will be available in written form to all participating psy-
chotherapists. Adherence to the treatment manual is en-
sured by the intensive training before the intervention
phase, by regular supervision and by controlling the ses-
sion documentation.
Outcome measures
Primary outcome measures for a person with Alzheimer’s
disease
The primary outcome measure will be level of depres-
sion in the patient with Alzheimer’s disease. Depressive
symptoms will be measured using a short form of the
Geriatric Depression Scale [56] and the Cornell Scale for
Depression in Dementia [57]. Depressive disorders will
be assessed using the Structured Clinical Interview for
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Table 1 Description of sessions
No Topic Therapeutic strategies Setting
Module 1: Diagnosis and goal setting
1 Diagnostic investigation Diagnostic interview: comprehensive assessment of affective and behavioural
symptoms, burden of caregiver, resources
Joint
2 Behaviour analysis and goal
setting
Analysis of situation, behaviours, emotion, cognition, consequences; setting
individual goals; planning interventions for joint and separate sessions
Joint
Module 2: Psychoeducation
3 Psychoeducation Providing information regarding disease, course, cause, medication, psychosocial
interventions, support possibilities; adopting external memory aids (notebook, lists,
signs for orientation, etc.); introducing mood journal
Joint
Module 3: Engagement in pleasant activities
4 Setting the stage for
pleasant activities
Explaining relation of behaviour (e.g., inactivity), mood (e.g., depression), neuronal
degeneration and cognitive decline; developing a personal list of pleasant
activities; introducing activity journal
Joint
5 Planning of pleasant
activities
Selection of pleasant (social, physical, leisure) activities; planning of pleasant
activities in a structured weekly schedule
Possibly without caregiver
6 Establishing regular
activities
Discussing problems and progress with regular pleasant activities; motivation
strategies to form habits (reinforcing by rewards; positive self-talk); introducing
thought journal
Joint
Module 4: Cognitive restructuring
7 Setting the stage for
cognitive restructuring
Assessing typical negative (depression, anxiety, or anger related) and positive
thoughts; completing the event–thought–emotion schema on the basis of recent
examples; finding alternative thoughts
Joint
8 Challenging negative
thoughts
Repetition of event–thought–emotion schema; challenging dysfunctional
thoughts; repetition of finding alternative thoughts; describing thought control
techniques (card and signal techniques)
Possibly without caregiver
9 Practising helpful thoughts Discussing problems and progress with thought control techniques; strategies for
practising helpful thoughts; introducing life review: structure and tools (e.g.,
photographs)
Joint
Module 5: Life review
10 Childhood Reminiscence of positive experiences in childhood 1 or 2 sessions joint, 2 or 3
sessions without caregiver
11 Adolescence Reminiscence of positive experiences in adolescence
12 Young adulthood Reminiscence of positive experiences in young adulthood
13 Older adulthood Reminiscence of positive experiences in older adulthood; integration: review
significant successes, reframe difficult times
Module 6: Training caregiver in behaviour management techniques
14 Setting the stage for
behaviour management
Identifying problem behaviours, their precursors and consequences; describing
the techniques: planning and implementing an intervention; evaluating an
intervention; providing the caregiver (and patient) with methods to change
precursors and consequences of behaviour (part 1)
Joint
15 Changing problem
behaviour, part 1
Discussing the methods to change precursors and consequences of behaviour
(part 1); discussing progress; discussing methods to change precursors and
consequences of behaviour (part 2)
Joint
16 Changing problem
behaviour, parts 2 and 3
Discussing progress; discussing the methods to change precursors and
consequences of behaviour (part 3) (or repetition of behaviour parts 1 and 2)
Possibly without patient
Module 7: Interventions for the caregiver (parallel to sessions 4–16)
i Stress management and
emotion regulation
Analyzing stressors, thoughts, emotional and behavioural reactions; self-
monitoring of thought and behaviour; training in problem solving, cognitive re-
framing, relaxation techniques
Only caregiver
ii Pleasant activities Developing a personal list of pleasant activities; keeping an activity journal;
selection of pleasant (social, physical, leisure) activities; planning of pleasant
activities in a structured weekly schedule; discussing problems and progress with
regular pleasant activities
Only caregiver
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DSM-IV Axis I Disorders [58]. The diagnosis of depres-
sion is based on the criteria for major and minor depres-
sion of the Diagnostic and Statistical Manual of Mental
Disorders IV (Text Revision) [59] and on the provisional
diagnostic criteria for depression in Alzheimer’s disease
[60]. Both the Cornell Scale for Depression in Dementia
and the Geriatric Depression Scale are widely used;
while the Geriatric Depression Scale is most appropriate
for pre-clinical and mild dementia, the Cornell Scale for
Depression in Dementia can also be applied when the
severity of dementia is increasing.
Secondary outcome measures for a person with Alzheimer’s
disease
Other emotional and behavioural symptoms will be
measured using the Neuropsychiatric Inventory [61]
and the Apathy Evaluation Scale [62]. The Neuro-
psychiatric Inventory is a structured interview with a
caregiver, addressing 12 behavioural and affective do-
mains common in dementia, agitation, irritability,
anxiety, dysphoria, hallucinations, delusions, apathy,
euphoria, disinhibition, aberrant motor behaviour,
night-time disturbances and appetite and eating ab-
normalities. The Apathy Evaluation Scale is an assess-
ment scale for apathy, and has been validated for
patients with Alzheimer’s disease and other
dementias.
The quality of life is measured by the Quality of Life
(Alzheimer’s Disease) Instrument [63]. It is based on dir-
ect interviews with patients with Alzheimer’s disease and
a questionnaire completed by caregivers. The advantage
of the Quality of Life (Alzheimer’s Disease) Instrument
over other scales is that the caregiver version can also be
applied to severe stages of Alzheimer’s disease.
The preferred coping strategies for the patient are
assessed using the Stress Coping Inventory [64]. It in-
cludes 20 subscales, which allow differentiation
between strategies targeting stress reduction (‘positive
strategies’, e.g., social support, positive self-instruction)
and stress increase (‘negative strategies’, e.g., avoid-
ance, resignation).
Secondary outcome measures for a caregiver
The caregiver’s burden, i.e., the psychological, psycho-
social, physical and financial burden of providing care
for a patient with Alzheimer’s disease, is measured
using the Zarit Burden Interview [65] and the follow-
ing well-being and quality of life measures: the Centre
for Epidemiologic Studies Depression Scale [66], the
trait scale of the State Trait Anxiety Inventory [67],
the anger-in and anger-out scales of the State Trait
Anger Expression Inventory [68], the Satisfaction
With Life Scale [69], the 12-item Short-Form Health
Survey [70] and the Stress Coping Inventory [64].
Neuropsychological assessment and diagnostic
procedures
The patient’s cognitive function is primarily tested with
the Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) Neuropsychological Assessment Bat-
tery [71]. Further cognitive tests are added, to ensure at
least two tests per domain. This battery includes:
 Screening The Mini Mental State Examination [54];
 Memory The CERAD Word List Memory Test
(learning, recall and recognition) [72]; a German
version of the Auditory Verbal Learning Test [73];
the Corsi Block Task (forward and backward series)
[74];
 Language The CERAD Animal Naming Task [75]; a
modified Boston Naming Test [76]; the Controlled
Oral Word Association Test [77];
 Praxis The CERAD Constructional Praxis [78]; the
Rey–Osterrieth Complex Figure Test [79]; the
Table 1 Description of sessions (Continued)
iii Social support Analyzing social support network; acceptance of formal and informal support
(including cognitive restructuring); strategies of utilization of social support;
communication with others about burden
Only caregiver
iv… Approximately four sessions, but as many as needed Only caregiver
Module 8: Couples counselling
17 Setting the stage for
couples counselling
Analyzing emotions regarding relationship, wishes, expectations, fears, typical
conflicts, etc.; identifying core problems; oral history interview
Joint
18 Communication and joint
problem-solving training
Improving communication style (roles as speaker and listener), training
communication sequences; identify old and new coping strategies; establishing
joint activities; maintaining important elements
Joint
19 Acceptance and planning
for the future
Gradually challenging the view that everything is continuing normally; adapting
to new roles (dependence, responsibility); joint planning of future care with a
discussion of uncertainties and worries experienced by patient and caregiver
Joint
Closing of therapy
20 Summary and reflection Goal attainment scaling; evaluation of strategies; future planning Joint
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Picture Completion subtest of the Wechsler Adult
Intelligence Scale-III [80];
 Executive function Task switching: the Trail Making
Test, Part B [81]; Inhibition of prepotent responses:
the Stroop Color-Word Test [82]; Updating working
memory: Digit Span Backward from the Wechsler
Adult Intelligence Scale-III [80];
 Attention The Trail Making Test, Part A [81]; the
Digit Symbol Substitution Test from the Wechsler
Adult Intelligence Scale-III [80].
Activities of daily living will be assessed using the
Barthel Index [83], which is the standard measure in
German-speaking countries [84]. Instrumental activities
of daily living will be assessed using the Bayer Activities
of Daily Living Scale [85], which is a 25-item, informant-
rated, internationally used questionnaire with established
validity and reliability.
Global clinical assessment of severity will be per-
formed using the Clinical Dementia Rating Scale [53].
A trained neuropsychologist will test all patients.
Together with neurologists and psychiatrists, the diag-
nosis of probable Alzheimer’s disease will be made ac-
cording to the Diagnostic and Statistical Manual of
Mental Disorders IV (Text Revision) and NINCDS–
ADRDA criteria for Alzheimer’s disease [52]. The
NINCDS–ADRDA criteria require a history of cogni-
tive decline and evidence of impairment in memory
and at least one other cognitive domain. Possible
cases of Alzheimer’s disease (in NINCDS–ADRDA
terminology) will also be included, i.e. persons who
meet these criteria and also have another condition
thought to be contributing to cognitive impairment
will be included. To exclude a serious cerebral lesion,
such as infection or a local lesion, all subjects will
undergo magnetic resonance imaging within 6 months
of the diagnosis.
For safety and to maintain oversight of the study, an
electronic case report form provided by the Clinical
Trial Centre of the University Hospital Zurich will be
completed after each information, assessment and ther-
apy session. The case report form contains checklists,
test results, information about the patient (other therap-
ies, medications, problems, etc.), adverse events, dates of
assessments and the names of the investigators. The par-
ticipants will be screened regularly for suicidality. In the
case of an increased suicidality risk, even if not expected,
the patients will be withdrawn from the study by the re-
search team.
Methods against biases
The proposed study employs several methods to avoid
biases:
 Selection bias The randomization procedure is the
gold standard to avoid this bias.
 Detection bias The baseline assessment is made
before randomization to avoid this bias. In addition,
the therapists will not collect any outcome data t
post-test or follow-up assessments. This will be done
by blinded members of the research team (single-
blinded trial). Research assistants and therapists will
be instructed during their training on the import-
ance of maintaining the blinded status. The partici-
pants will be asked not to comment at post-test or
follow-up assessments on the nature of their in-
volvement in the study.
 Performance bias (intervention fidelity) To confirm
that the intervention has been delivered and
received as intended, a standardization procedure
(manual, extensive training and session
documentation, including an adherence checklist
and supervision) has been established.
 Attrition bias Statistical analysis will include
techniques to minimize a possible attrition bias, i.e.,
intention-to-treat analysis and imputing missing
data. In the case of dropping out, it is intended to
continue data collection whenever possible.
Statistical analysis
Several analytical strategies are planned, to test the
efficacy of the intervention. First, ANOVAs will be
conducted to compare the mean outcome in depres-
sive symptoms. The sex, age, caregiver’s relationship
(spouse, child, close friend) and severity of cognitive
impairment and depressive symptoms at baseline will
be considered covariates. Second, individual growth
curves will be analyzed, i.e., the rates and shapes of
changes will be examined and individual growth
curves will be compared, to investigate the differ-
ences. Third, multivariate analyses will be used to test
the effect of the intervention with regard to the sec-
ondary and caregiver outcome measures. In this way,
correlations between the outcome measures can be
considered. Post-hoc analyses will be performed fol-
lowing a significant overall effect.
A complete dataset will be available if all four tests
(pre-test, post-test and follow-ups 1 and 2) have been
completed. Dropping out can occur if a participant (1)
does not complete the pre-test, (2) decides, after infor-
mation or randomization, against participation, or (3)
starts with the treatment, but discontinues it. If fewer
than 20 % of the items of one’s self-report instrument
are missing, the missing values are imputed using the
mean of the scale for this participant. If the whole scale
is missing, the value will be imputed using the
expectation-maximization algorithm.
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The data and all appropriate documentation will be
stored for a minimum of 10 years after the completion
of the study, including the follow-up period.
Regulatory issues
Ethical approval
Ethical approval has been obtained through the Swiss
Ethics Committee in the Canton of Zurich (reference
number 2009–0078/3). The study will be conducted in
accordance with the principles enunciated in the current
Declaration of Helsinki, the Guidelines of Good Clinical
Practice issued by the International Conference on Har-
monisation and the Swiss regulatory authority’s require-
ments. Participation in the study is voluntary. There are
no negative consequences for non-participation or drop-
ping out. Patients who decline to participate or drop out
receive medical and psychosocial care as usual. The par-
ticipants are informed of the study conditions in detail
(verbally and in writing) and specific questions can be
discussed. Ethical challenges may arise as a result of
randomization. However, the control conditions are ac-
tive treatment conditions, so participants in any study
condition will benefit if they enrol in the study.
Consent
Consent to enter the study will be sought from each par-
ticipant only after a full explanation has been given, an
information leaflet offered and time allowed for consid-
eration. Signatures to indicate participants’ consent will
be obtained. The right of the participant to refuse to par-
ticipate without giving reasons will be respected. After
participants have entered the study, clinicians remain
free to provide an alternative treatment to that specified
in the protocol at any stage, if they consider it to be in
the participant’s best interest, but the reasons for doing
so will be recorded. In these cases, the participants re-
main within the study for the purposes of follow-up and
data analysis. All participants are free to withdraw at any
time from the protocol treatment without giving reasons
and without prejudicing further treatment.
Confidentiality
The principal investigator will preserve the confidential-
ity of the participants in the study and is registered
under the Data Protection Act.
Insurance
Insurance coverage will be provided by Zurich
Versicherungsgesellschaft, Zurich, Switzerland (policy
number 9.730.682), for a maximum of 3,000,000 Swiss
francs.
Audits
The study may be subject to inspection and audit by
regulatory bodies, to ensure adherence to the Guidelines
of Good Clinical Practice, national law and regulatory
requirements. The auditor will be independent from the
investigators and the sponsor.
Adverse events
An adverse event is any untoward medical or psycho-
logical occurrence in a study subject, e.g., worsening
of symptoms. A serious adverse event is any unto-
ward medical or psychological occurrence or effect
that results in death, is life-threatening (this refers to
an event in which the subject was at risk of death at
the time of the event but does not refer to an event
which hypothetically might have caused death had it
been more severe), requires hospitalization or pro-
longation of existing inpatients’ hospitalization, or re-
sults in persistent or significant disability or
incapacity. Medical or psychological judgement will
be exercised in deciding whether an adverse event is
serious. Important adverse events that are not imme-
diately life-threatening or do not result in death or
hospitalization but may jeopardize the subject or may
require intervention to prevent one of the other out-
comes listed in the serious adverse event definition
will also be considered serious.
All adverse events will be reported. Depending on the
nature of the event, the following reporting procedures
will be followed:
 Non-serious adverse events All such events, whether
expected or not, will be recorded.
 Serious adverse events A serious adverse event form
will be completed and faxed to the principal
investigator within 24 hours. However,
hospitalizations for an elective treatment of a pre-
existing condition does not need to be reported as a
serious adverse event.
The principal investigator will assess whether the
event is:
 ‘related’, i.e. results from the administration of any of
the research procedures;
 ‘unexpected’, i.e. is not listed in the protocol as an
expected occurrence.
Reports of suspected related and unexpected serious
adverse events will be submitted to the ethics com-
mittee within 15 days (or within 7 days for fatal or
life-threatening serious adverse events) of an investi-
gator becoming aware of the event.
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Discussion
This trial is a CBT-based, multicomponent treatment
implemented with state-of-the-art randomized con-
trolled trial methodology. A recent report on national
dementia strategies concludes that any national demen-
tia plan should include, among other things, the goals of
improving early diagnosis and treatment, of improving
support to the person with dementia living at home, as
well as to the caregiver, and of improving training for
healthcare professionals [86]. This trial has the potential
to establish an empirically based psychological treatment
for non-cognitive symptoms that reduce the quality of
life of the person with dementia and the caregiver. The
treatment manual will be published and training work-
shops will be offered, so that the information can be
widely spread among healthcare professionals. This
CBT-based treatment is potentially a side-effect-free al-
ternative to medication for neuropsychiatric symptoms.
In the case of affective and behavioural symptoms, there
is a strong case for psychosocial intervention prior to
resorting to medication [87]. Furthermore, health care
costs might be reduced through decreased use of medi-
cation and delayed nursing home placement.
This treatment approach focuses not only on the per-
son with dementia, but also on the caregiver and on the
dyad. It will empower the caregiver to take part in the
treatment and, at the same time, will improve the care-
giver’s own mental health and well-being.
Treatment guidelines list a larger number of psycho-
social interventions for dementia. However, empirical
evidence for many of the approaches is lacking, as recent
reviews conclude [9–11]. This trial, with state-of-the-art
methodology, has the potential to provide evidence for
future guidelines for the psychological treatment of
people with dementia and their caregivers.
Trial status
The trial is in the recruiting phase at the time of manu-
script submission.
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